Pneumologie 2020; 74(S 01): 40
DOI: 10.1055/s-0039-3403150
DOI: 10.1055/s-0039-3403150
Posterbegehung (PO07) – Sektion Pneumologische Onkologie
Immunonkologische Therapie beim Lungenkarzinom
PD-L1-Expression im Primärtumor vs. Metastase in Proben der Phase-III-Studie MYSTIC bei 1st-Line metastasiertem NSCLC
T Wehler
1
Evangelisches Krankenhaus Hamm, Germany
,
N Reinmuth
2
Thoracic Oncology Department, Asklepios Lung Clinic, Munich-Gauting, Germany
,
AM Boothman
3
Oncology Companion Diagnostics Unit, Precision Medicine and Genomics, Imed Biotech
Unit, Astrazeneca, Cambridge, United Kingdom
,
BC Cho
4
Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine,
Seoul, Korea, Republic of
,
KH Lee
5
Medical Oncology, Chungbuk National University Hospital, Cheongju, Korea, Republic
of
,
A Luft
6
Oncology Department, Leningrad Regional Clinical Hospital, Lunacharskogo Prospect,
Russian Federation
,
JC Ahn
7
Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University, Seoul, Korea,
Republic of
,
M Scott
8
Diagnostic Development Unit, Precision Medicine, R&d Oncology, Astrazeneca, Cambridge,
United Kingdom
,
J Whiteley
8
Diagnostic Development Unit, Precision Medicine, R&d Oncology, Astrazeneca, Cambridge,
United Kingdom
,
J Walker
9
Oncology Companion Diagnostics Unit, Precision Medicine and Genomics, Imed Biotech
Unit, Astrazeneca, Cambridge, United Kingdom
,
V Karwe
10
Biostatistics, Astrazeneca, Gaithersburg, MD, United States of America
,
P Mukhopadhyay
11
Global Medicines Development, Astrazeneca, Cambridge, United Kingdom
,
P Thiyagarajah
11
Global Medicines Development, Astrazeneca, Cambridge, United Kingdom
,
U Scheuring
11
Global Medicines Development, Astrazeneca, Cambridge, United Kingdom
,
N Rizvi
12
Medical Oncology, Columbia University Medical Center, New York, United States of America
,
M de Wit
13
Vivantes Netzwerk für Gesundheit GmbH, Berlin, Germany
› Institutsangaben
